MCID: LTR001
MIFTS: 53

Lateral Sclerosis malady

Categories: Rare diseases, Neuronal diseases, Genetic diseases

Aliases & Classifications for Lateral Sclerosis

Aliases & Descriptions for Lateral Sclerosis:

Name: Lateral Sclerosis 12 14 69
Primary Lateral Sclerosis 12 50 51 52
Adult-Onset Primary Lateral Sclerosis 12 50
Motor Neuron Disease 42 69
Adult-Onset Pls 50

Classifications:



External Ids:

Disease Ontology 12 DOID:230
ICD10 33 G12.29
ICD9CM 35 335.24
MeSH 42 D016472
SNOMED-CT 64 81211007
UMLS 69 C0154682

Summaries for Lateral Sclerosis

NINDS : 51 Primary lateral sclerosis (PLS) is a rare neuromuscular disease with slowly progressive weakness in voluntary muscle movement. PLS belongs to a group of disorders known as motor neuron diseases. PLS affects the upper motor neurons (also called corticospinal neurons) in the arms, legs, and face.  It occurs when nerve cells in the motor regions of the cerebral cortex (the thin layer of cells covering the brain which is responsible for most higher level mental functions) gradually degenerate, causing movements to be slow and effortful.  The disorder often affects the legs first, followed by the body, trunk, arms and hands, and, finally the bulbar muscles (muscles that control speech, swallowing, and chewing).  Symptoms include weakness, muscle stiffness and spasticity, clumsiness, slowing of movement, and problems with balance and speech. PLS is more common in men than in women, with a varied gradual onset that generally occurs between ages 40 and 60. PLS progresses gradually over a number of years, or even decades. Scientists do not believe PLS has a simple hereditary cause.  The diagnosis of PLS requires extensive testing to exclude other diseases. When symptoms begin, PLS may be mistaken for amyotrophic lateral sclerosis (ALS) or spastic paraplegia.  Most neurologists follow an affected individual's clinical course for at least 3 to 4 years before making a diagnosis of PLS.

MalaCards based summary : Lateral Sclerosis, also known as primary lateral sclerosis, is related to primary lateral sclerosis, juvenile and amyotrophic lateral sclerosis 10, with or without ftd, and has symptoms including ataxia, muscular fasciculation and hemiplegia. An important gene associated with Lateral Sclerosis is ALS2 (ALS2, Alsin Rho Guanine Nucleotide Exchange Factor), and among its related pathways/superpathways are Neuroscience and Amyotrophic lateral sclerosis (ALS). The drugs Riluzole and Mexiletine have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and cortex, and related phenotypes are shRNA abundance <= 50% and behavior/neurological

Disease Ontology : 12 A motor neuron disease characterized by painless but progressive weakness and stiffness of the muscles of the legs.

NIH Rare Diseases : 50 primary lateral sclerosis (pls) is a rare neuromuscular disease that affects the nerve cells that control the voluntary muscles. problems in the legs (such as weakness, stiffness, spasticity, and balance problems) are often observed first, but hand clumsiness and changes in speech can be early symptoms, as well. the condition is progressive (gradually becomes worse over time); however, affected people have a normal life expectancy. the underlying cause of adult pls is currently unknown. in most cases, it occurs sporadically in people with no family history of the condition. a subtype of pls, called juvenile pls, is caused by changes (mutations) in the als2 gene and is inherited in an autosomal recessive manner. treatment is based on the signs and symptoms present in each person. last updated: 4/14/2017

Related Diseases for Lateral Sclerosis

Diseases in the Lateral Sclerosis family:

Primary Lateral Sclerosis, Juvenile Primary Lateral Sclerosis, Adult, 1

Diseases related to Lateral Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 235)
id Related Disease Score Top Affiliating Genes
1 primary lateral sclerosis, juvenile 33.9 ALS2 ALS2CR12 SOD1
2 amyotrophic lateral sclerosis 10, with or without ftd 33.7 ALS2 ANG FUS TARDBP
3 amyotrophic lateral sclerosis 1 12.5
4 amyotrophic lateral sclerosis-parkinsonism/dementia complex 12.4
5 amyotrophic lateral sclerosis 8 12.4
6 amyotrophic lateral sclerosis 4, juvenile 12.3
7 frontotemporal dementia and/or amyotrophic lateral sclerosis 1 12.3
8 amyotrophic lateral sclerosis 2, juvenile 12.3
9 amyotrophic lateral sclerosis 11 12.3
10 amyotrophic lateral sclerosis 6, with or without frontotemporal dementia 12.3
11 amyotrophic lateral sclerosis 9 12.3
12 amyotrophic lateral sclerosis 17 12.3
13 amyotrophic lateral sclerosis 16, juvenile 12.3
14 amyotrophic lateral sclerosis 15, with or without frontotemporal dementia 12.3
15 amyotrophic lateral sclerosis 18 12.2
16 frontotemporal dementia and/or amyotrophic lateral sclerosis 2 12.2
17 juvenile amyotrophic lateral sclerosis 12.2
18 amyotrophic lateral sclerosis 19 12.2
19 amyotrophic lateral sclerosis 12 12.2
20 amyotrophic lateral sclerosis 20 12.2
21 amyotrophic lateral sclerosis 14, with or without frontotemporal dementia 12.2
22 frontotemporal dementia and/or amyotrophic lateral sclerosis 4 12.2
23 amyotrophic lateral sclerosis 3 12.2
24 amyotrophic lateral sclerosis 7 12.2
25 amyotrophic lateral sclerosis type 10 12.2
26 amyotrophic lateral sclerosis 21 12.2
27 frontotemporal dementia and/or amyotrophic lateral sclerosis 3 12.2
28 amyotrophic lateral sclerosis type 5 12.2
29 primary lateral sclerosis, adult, 1 12.2
30 amyotrophic lateral sclerosis 5, juvenile 12.2
31 amyotrophic lateral sclerosis 22 with or without frontotemoral dementia 12.2
32 amyotrophic lateral sclerosis type 14 12.2
33 juvenile amyotrophic lateral sclerosis with dementia 12.1
34 amyotrohpic lateral sclerosis type 22 12.1
35 tardbp-related amyotrophic lateral sclerosis 12.1
36 sod1-related amyotrophic lateral sclerosis 12.0
37 c9orf72-related amyotrophic lateral sclerosis and frontotemporal dementia 12.0
38 autosomal recessive juvenile amyotrophic lateral sclerosis 12.0
39 optn-related amyotrophic lateral sclerosis 11.9
40 pfn1-related amyotrophic lateral sclerosis 11.9
41 setx-related amyotrophic lateral sclerosis 11.9
42 als5-related amyotrophic lateral sclerosis 11.9
43 erbb4-related amyotrophic lateral sclerosis 11.9
44 hnrnpa1-related amyotrophic lateral sclerosis 11.9
45 fig4-related amyotrophic lateral sclerosis 11.9
46 sigmar1-related amyotrophic lateral sclerosis 11.9
47 sqstm1-related amyotrophic lateral sclerosis 11.9
48 ubqln2-related amyotrophic lateral sclerosis/frontotemporal dementia 11.9
49 vapb-related amyotrophic lateral sclerosis 11.9
50 vcp-related amyotrophic lateral sclerosis/frontotemporal dementia 11.9

Graphical network of the top 20 diseases related to Lateral Sclerosis:



Diseases related to Lateral Sclerosis

Symptoms & Phenotypes for Lateral Sclerosis

UMLS symptoms related to Lateral Sclerosis:


ataxia, muscular fasciculation, hemiplegia, myoclonus

GenomeRNAi Phenotypes related to Lateral Sclerosis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.32 ANG DPP6 FUS HNRNPA1 RNF19A SETX

MGI Mouse Phenotypes related to Lateral Sclerosis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.65 ALS2 C9orf72 GRIA2 NEFH SETX SIGMAR1
2 nervous system MP:0003631 9.32 NEFH PRPH SLC1A2 SOD1 TARDBP VCP

Drugs & Therapeutics for Lateral Sclerosis

Drugs for Lateral Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 299)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Riluzole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 1744-22-5 5070
2
Mexiletine Approved Phase 4,Phase 2 31828-71-4 4178
3
Armodafinil Approved, Investigational Phase 4 112111-43-0
4
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
5 Anticonvulsants Phase 4,Phase 2,Phase 3
6 Excitatory Amino Acid Antagonists Phase 4,Phase 2,Phase 3
7 Excitatory Amino Acids Phase 4,Phase 2,Phase 3
8 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Phase 1
9 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
10 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1
11 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2
12 Diuretics, Potassium Sparing Phase 4,Phase 3,Phase 2
13 Sodium Channel Blockers Phase 4,Phase 3,Phase 2
14 Central Nervous System Stimulants Phase 4,Phase 1
15 Cytochrome P-450 CYP3A Inducers Phase 4
16 Wakefulness-Promoting Agents Phase 4
17
Olanzapine Approved, Investigational Phase 2, Phase 3 132539-06-1 4585
18
Lenograstim Approved Phase 2, Phase 3 135968-09-1
19
Antipyrine Approved Phase 3 60-80-0 2206
20
Acetylcholine Approved Phase 2, Phase 3 51-84-3 187
21
Ceftriaxone Approved Phase 3 73384-59-5 5479530 5361919
22
Dopamine Approved Phase 2, Phase 3, Phase 1 51-61-6, 62-31-7 681
23
Memantine Approved, Investigational Phase 2, Phase 3 19982-08-2 4054
24
Zinc Approved Phase 3,Phase 1,Phase 2 7440-66-6 32051 23994
25
Minocycline Approved, Investigational Phase 3,Phase 2 10118-90-8 5281021
26
Valproic Acid Approved, Investigational Phase 3 99-66-1 3121
27
Citalopram Approved Phase 3 59729-33-8 2771
28
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 11953898 5460373 44475014
29
Pramipexole Approved, Investigational Phase 3,Phase 2,Phase 1 104632-26-0 59868 119570
30
Dextromethorphan Approved Phase 3,Phase 2 125-71-3 5360696 5362449
31
Guaifenesin Approved, Vet_approved Phase 3,Phase 2 93-14-1 3516
32
Quinidine Approved Phase 3,Phase 2 56-54-2 441074
33
Creatine Approved, Nutraceutical Phase 3,Phase 2 57-00-1 586
34
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
35
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380
36
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 59-30-3 6037
37 Superoxide Dismutase Phase 2, Phase 3,Phase 1
38 Antiemetics Phase 2, Phase 3
39 Antipsychotic Agents Phase 2, Phase 3
40 Autonomic Agents Phase 2, Phase 3, Phase 1
41 Central Nervous System Depressants Phase 2, Phase 3, Phase 1
42 Gastrointestinal Agents Phase 2, Phase 3,Phase 1
43 Neurotransmitter Uptake Inhibitors Phase 2, Phase 3, Early Phase 1
44 Peripheral Nervous System Agents Phase 2, Phase 3, Phase 1, Early Phase 1
45 Psychotropic Drugs Phase 2, Phase 3, Phase 1, Early Phase 1
46
Serotonin Phase 2, Phase 3, Early Phase 1 50-67-9 5202
47 Serotonin Agents Phase 2, Phase 3, Early Phase 1
48 Serotonin Uptake Inhibitors Phase 2, Phase 3, Early Phase 1
49 Tranquilizing Agents Phase 2, Phase 3, Phase 1
50 Anesthetics Phase 2, Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 402)
id Name Status NCT ID Phase
1 Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis Unknown status NCT00560287 Phase 4
2 CARE Canadian ALS Riluzole Evaluation Completed NCT00542412 Phase 4
3 Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS) Completed NCT00613899 Phase 4
4 Mexiletine for the Treatment of Muscle Cramps in ALS Completed NCT01811355 Phase 4
5 Modafinil for Treatment of Fatigue in ALS Patients Completed NCT00614926 Phase 4
6 Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis Unknown status NCT00706147 Phase 2, Phase 3
7 Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS) Unknown status NCT00876772 Phase 2, Phase 3
8 Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis Unknown status NCT00069186 Phase 3
9 Clinical Value of Noninvasive Intracranial Pressure Measurement Unknown status NCT02130219 Phase 2, Phase 3
10 Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) Completed NCT00868166 Phase 2, Phase 3
11 Safety Extension Study of TRO19622 in ALS Completed NCT01285583 Phase 2, Phase 3
12 Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III Completed NCT00415519 Phase 3
13 Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00125203 Phase 2, Phase 3
14 Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis Completed NCT01492686 Phase 3
15 Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Completed NCT00330681 Phase 3
16 Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease Completed NCT01776970 Phase 2, Phase 3
17 Clinical Trial Ceftriaxone in Subjects With ALS Completed NCT00349622 Phase 3
18 Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS Completed NCT00372879 Phase 3
19 Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT01933321 Phase 2, Phase 3
20 Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS) Completed NCT00353665 Phase 2, Phase 3
21 Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial Completed NCT00035815 Phase 3
22 Minocycline to Treat Amyotrophic Lateral Sclerosis Completed NCT00047723 Phase 3
23 Repetitive Transcranial Magnetic Stimulation (rTMS) in Amyotrophic Lateral Sclerosis Completed NCT00833820 Phase 2, Phase 3
24 Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls Completed NCT01160263 Phase 3
25 Trial of Sodium Valproate in Amyotrophic Lateral Sclerosis Completed NCT00136110 Phase 3
26 Escitalopram (Lexapro) for Depression MS or ALS Completed NCT00965497 Phase 3
27 Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement Completed NCT00386464 Phase 2, Phase 3
28 The Objective is to Compare the Efficacy and Safety of Masitinib in Combination With Riluzole in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) Completed NCT02588677 Phase 2, Phase 3
29 A Study in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00444613 Phase 2, Phase 3
30 Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00424463 Phase 3
31 The Effect of GCSF in the Treatment of ALS Patients Completed NCT01825551 Phase 2, Phase 3
32 Phase 3 Study of Dexpramipexole in ALS Completed NCT01281189 Phase 3
33 Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS Completed NCT00021697 Phase 3
34 Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS Completed NCT00573443 Phase 3
35 Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects Completed NCT01994109 Phase 3
36 Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect) Active, not recruiting NCT01257828 Phase 3
37 A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS) Active, not recruiting NCT00445172 Phase 2, Phase 3
38 Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year Active, not recruiting NCT02496767 Phase 3
39 A Study for Patients Who Completed VITALITY-ALS (CY 4031) Enrolling by invitation NCT02936635 Phase 3
40 Phase 3 Study to Compare the Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients Not yet recruiting NCT03127267 Phase 3
41 Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders Terminated NCT00839033 Phase 3
42 Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS) Terminated NCT00818389 Phase 2, Phase 3
43 Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS) Terminated NCT01016522 Phase 3
44 Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation Terminated NCT01583088 Phase 3
45 Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS) Terminated NCT00211224 Phase 3
46 Phase 3 Extension Study of Dexpramipexole in ALS Terminated NCT01622088 Phase 3
47 Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS) Unknown status NCT01232738 Phase 2
48 A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS) Unknown status NCT01935518 Phase 2
49 Transcranial Direct Current Stimulation as a Novel Therapeutic Approach in Amyotrophic Lateral Sclerosis Unknown status NCT01569958 Phase 2
50 Safety and Tolerability of Anakinra in Combination With Riluzol in Amyotrophic Lateral Sclerosis Unknown status NCT01277315 Phase 2

Search NIH Clinical Center for Lateral Sclerosis

Cochrane evidence based reviews: motor neuron disease

Genetic Tests for Lateral Sclerosis

Anatomical Context for Lateral Sclerosis

MalaCards organs/tissues related to Lateral Sclerosis:

39
Spinal Cord, Brain, Cortex, Testes, Endothelial, Skin, Skeletal Muscle

Publications for Lateral Sclerosis

Articles related to Lateral Sclerosis:

(show top 50) (show all 2254)
id Title Authors Year
1
Early recurrence of Tako-Tsubo cardiomyopathy in an elderly woman with amyotrophic lateral sclerosis: different triggers inducing different apical ballooning patterns. ( 28079765 )
2017
2
C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia. ( 28334866 )
2017
3
Deep learning predictions of survival based on MRI in amyotrophic lateral sclerosis. ( 28070484 )
2017
4
An Objective Functional Characterisation of Head Movement Impairment in Individuals with Neck Muscle Weakness Due to Amyotrophic Lateral Sclerosis. ( 28068376 )
2017
5
A novel amyotrophic lateral sclerosis mutation in OPTN induces ER stress and Golgi fragmentation in vitro. ( 27534431 )
2017
6
Percutaneous endoscopic gastrostomy, body weight loss and survival in amyotrophic lateral sclerosis: a population-based registry study. ( 28076984 )
2017
7
Sweet food preference in amyotrophic lateral sclerosis. ( 28073920 )
2017
8
Longitudinal assessment of metal concentrations and copper isotope ratios in the G93A SOD1 mouse model of amyotrophic lateral sclerosis. ( 28067393 )
2017
9
Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease. ( 28072907 )
2017
10
Visual encoding, consolidation, and retrieval in amyotrophic lateral sclerosis: executive function as a mediator, and predictor of performance. ( 28084080 )
2017
11
HuR promotes the molecular signature and phenotype of activated microglia: Implications for amyotrophic lateral sclerosis and other neurodegenerative diseases. ( 28300326 )
2017
12
Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial. ( 28070747 )
2017
13
Association analysis of polymorphisms in VMAT2 and TMEM106B genes for Parkinson's disease, amyotrophic lateral sclerosis and multiple system atrophy. ( 28477711 )
2017
14
Death wish in patients with amyotrophic lateral sclerosis. ( 28084231 )
2017
15
Absolute quantification of myosin heavy chain isoforms by selected reaction monitoring can underscore skeletal muscle changes in a mouse model of amyotrophic lateral sclerosis. ( 28078418 )
2017
16
Linking Amyotrophic Lateral Sclerosis and Spinal Muscular Atrophy through RNA-transcriptome homeostasis: a genomics perspective. ( 28054357 )
2017
17
Organophosphate neurotoxicity to the voluntary motor system on the trail of environment-caused amyotrophic lateral sclerosis: the known, the misknown, and the unknown. ( 28070599 )
2017
18
An insight into death wish among patients with amyotrophic lateral sclerosis in India using "Wish-to-Die Questionnaire". ( 28084237 )
2017
19
Lead, cadmium and mercury in cerebrospinal fluid and risk of amyotrophic lateral sclerosis: A case-control study. ( 28089071 )
2017
20
Up-regulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis. ( 28069688 )
2017
21
Genetics insight into the amyotrophic lateral sclerosis/frontotemporal dementia spectrum. ( 28087719 )
2017
22
Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease. ( 28067943 )
2017
23
Orofacial function and monitoring of oral care in amyotrophic lateral sclerosis. ( 28079403 )
2017
24
Motor-evoked potential gain is a helpful test for the detection of corticospinal tract dysfunction in amyotrophic lateral sclerosis. ( 28068522 )
2016
25
SLC1A2 rs3794087 are associated with susceptibility to Parkinson's disease, but not essential tremor, amyotrophic lateral sclerosis or multiple system atrophy in a Chinese population. ( 27206883 )
2016
26
Cerebellar neuronal loss in amyotrophic lateral sclerosis cases with ATXN2 intermediate repeat expansions. ( 26599997 )
2016
27
The heat shock response plays an important role in TDP-43 clearance: evidence for dysfunction in amyotrophic lateral sclerosis. ( 26936937 )
2016
28
[Lower urinary tract dysfunction and neuropathological findings of the neural circuits controlling micturition in familial amyotrophic lateral sclerosis with L106V mutation in the SOD1 gene]. ( 26754593 )
2016
29
Alteration of Motor Protein Expression Involved in Bidirectional Transport in Peripheral Blood Mononuclear Cells of Patients with Amyotrophic Lateral Sclerosis. ( 26954557 )
2016
30
Lack of association between the Angiogenin (ANG) rs11701 polymorphism and amyotrophic lateral sclerosis risk: a meta-analysis. ( 26753798 )
2016
31
Epidemiology of Amyotrophic Lateral Sclerosis: A Population-Based Study in Israel. ( 27617889 )
2016
32
Polymorphisms in protein disulfide isomerase are associated with sporadic amyotrophic lateral sclerosis in the Chinese Han population. ( 26000911 )
2016
33
MATR3 mutation analysis in a Chinese cohort with sporadic amyotrophic lateral sclerosis. ( 26708275 )
2016
34
Osteopathic Manual Treatment for Amyotrophic Lateral Sclerosis: A Feasibility Pilot Study. ( 27651843 )
2016
35
Enhancing NAD+ Salvage Pathway Reverts the Toxicity of Primary Astrocytes Expressing Amyotrophic Lateral Sclerosis-linked Mutant Superoxide Dismutase 1 (SOD1). ( 27002158 )
2016
36
No association of GPNMB rs156429 polymorphism with Parkinson's disease, amyotrophic lateral sclerosis and multiple system atrophy in Chinese population. ( 27132081 )
2016
37
Nonnative SOD1 trimer is toxic to motor neurons in a model of amyotrophic lateral sclerosis. ( 26719414 )
2016
38
Screening of SOD1, FUS and TARDBP genes in patients with amyotrophic lateral sclerosis in central-southern China. ( 27604643 )
2016
39
C9orf72 expansion differentially affects males with spinal onset amyotrophic lateral sclerosis. ( 27663272 )
2016
40
Cerebral Degeneration in Amyotrophic Lateral Sclerosis Revealed by 3-Dimensional Texture Analysis. ( 27064416 )
2016
41
Physiology of the fasciculation potentials in amyotrophic lateral sclerosis: which motor units fasciculate? ( 27638031 )
2016
42
Prospects for bone marrow cell therapy in amyotrophic lateral sclerosis: how far are we from a clinical treatment? ( 27651758 )
2016
43
Black hairy tongue in a patient with amyotrophic lateral sclerosis. ( 27011938 )
2016
44
Mutational analysis of TBK1 in Taiwanese patients with amyotrophic lateral sclerosis. ( 26804609 )
2016
45
Late-onset spastic paraplegia type 10 (SPG10) family presenting with bulbar symptoms and fasciculations mimicking amyotrophic lateral sclerosis. ( 27084214 )
2016
46
Effect of High-Frequency Oscillations on Cough Peak Flows Generated by Mechanical In-Exsufflation in Medically Stable Subjects With Amyotrophic Lateral Sclerosis. ( 27190224 )
2016
47
Amyotrophic Lateral Sclerosis in Northern Spain 40 Years Later: What Has Changed? ( 27188850 )
2016
48
Assessment of a multiple biomarker panel for diagnosis of amyotrophic lateral sclerosis. ( 27634542 )
2016
49
Two distinct clinical features and cognitive impairment in amyotrophic lateral sclerosis patients with TARDBP gene mutations in the Chinese population. ( 26639158 )
2016
50
The segmental diffusivity profile of amyotrophic lateral sclerosis associated white matter degeneration. ( 27207250 )
2016

Variations for Lateral Sclerosis

Expression for Lateral Sclerosis

Search GEO for disease gene expression data for Lateral Sclerosis.

Pathways for Lateral Sclerosis

Pathways related to Lateral Sclerosis according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.86 GRIA2 NEFH SLC1A2 SOD1 TARDBP
2
Show member pathways
11.16 ALS2 GRIA2 NEFH PRPH SLC1A2 SOD1

GO Terms for Lateral Sclerosis

Cellular components related to Lateral Sclerosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasmic vesicle GO:0031410 9.55 ANG C9orf72 SIGMAR1 SOD1 UBQLN2
2 axon GO:0030424 9.26 ALS2 NEFH SETX SLC1A2
3 growth cone GO:0030426 8.92 ALS2 ANG SETX SIGMAR1

Biological processes related to Lateral Sclerosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 regulation of GTPase activity GO:0043087 9.13 ALS2 ALS2CR12 SOD1
2 neurofilament cytoskeleton organization GO:0060052 8.62 NEFH SOD1

Sources for Lateral Sclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....